HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J To Put Johnson’s Bedtime Dispute To Rest With $5m Settlement

This article was originally published in The Rose Sheet

Executive Summary

Pending final approval in Illinois district court, Johnson & Johnson will pay $5m into a class action fund to settle litigation challenging “clinically proven” sleep claims attached to Johnson’s Baby Bedtime products.

You may also be interested in...



J&J Relaunches Johnson’s Baby Care As Greener, Gentler, With Fewer Ingredients

The overhaul in line with “modern parents’ preferences” could be what’s needed to rouse the sleepy brand and spur Consumer business growth.

J&J Highlights Plans For Reinventing Johnson’s Baby, Globalizing Aveeno

A planned restage of Johnson’s Baby will “completely reinvent the brand,” says Jorge Mesquita, global chairman of the J&J’s consumer division. Meanwhile, the firm is working to unfetter “captive” regional brands, expanding OGX and Aveeno across the globe while bringing Le Petit Marseillais to North America, among other growth initiatives.

Not Just J&J’s Problem: The Evolving Talc Litigation Landscape

Legal experts see cosmetic talc suits flaring along two tracks – either alleging the carcinogenicity of talc itself or linking cancer cases to asbestos-tainted talc sources. At least one attorney sees the latter as a potentially bigger threat to the cosmetics industry with the traditional pool of asbestos defendants drying up.

Related Content

Topics

UsernamePublicRestriction

Register

RS109014

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel